Biomarkers for screening, diagnosis, and monitoring of ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 1902-1912

  Kobayashi, Eiji ^a   Ueda, Yutaka ^a   Matsuzaki, Shinya ^a   Yokoyama, Takuhei ^a   Kimura, Toshihiro ^a   Yoshino, Kiyoshi ^a   Fujita, Masami ^a   Kimura, Tadashi ^a   Enomoto, Takayuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HAPTOGLOBIN; LYSOPHOSPHATIDIC ACID; MESOTHELIN; MICRORNA; ULINASTATIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TRANSVAGINAL ECHOGRAPHY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869203660     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0646     Document Type: Review

References (85)

1. World Health Organization [Internet]. GLOBOCAN 2008. [updated 2011 Dec; cited 2012 Feb 23]. Available from: http://globocan.iarc.fr/factsheets/ populations/factsheet.asp?uno=900.
2. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, AFIP Washington, DC: 1998.
3. Berek JS, editor. Novak's gynecology. 13th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
4. Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshino K, Fujita M, et al. Serum biomarkers for early detection of gynecologic cancers. Cancers 2010;2:1312-27.
5. Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010;277:95-105.
6. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7.
7. Kupesic S, Plavsic BM. Early ovarian cancer: 3-D power Doppler. Abdom Imaging 2006;31:613-9. (Pubitemid 46360854)
8. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170:81-5. (Pubitemid 24084035)
9. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200s-5s.
10. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
11. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008;199:215-23.
12. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58:24-38. (Pubitemid 38117046)
13. BuysSS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011;305:2295-303.
14. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414-20. (Pubitemid 351668303)
15. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
16. van Nagell JR Jr, Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011;118:1212-21.
17. Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13:18-26.
18. Sørensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58:A4331.
19. Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992;79:1002-10.
20. Scholl SM, Bascou CH, Mosseri V, Olivares R, Magdelenat H, Dorval T, et al. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer 1994;69:342-6. (Pubitemid 24046560)
21. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994;70:1188-90. (Pubitemid 24358961)
22. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-64.
23. Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:888-93. (Pubitemid 24316739)
24. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4. (Pubitemid 26246787)
25. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054-7. (Pubitemid 32976692)
26. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.
27. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44:147-54.
28. Koelma IA, Nap M, Rodenburg CJ, Fleuren GJ. The value of tumour marker CA 125 in surgical pathology. Histopathology 1987;11:287-94. (Pubitemid 17038276)
29. Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, et al. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest 1999;47:52-7. (Pubitemid 29026896)
30. Negishi Y, Furukawa T, Oka T, Sakamoto M, Hirata T, Okabe K, et al. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Gynecol Obstet Invest 1987;23:200-7. (Pubitemid 17068041)
31. Castelli M, Battaglia F, Scambia G, Panici PB, Ferrandina G, Mileo AM, et al. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Oncology 1991;48:13-7.
32. Castelli M, Romano P, Atlante G, Pozzi M, Ferrini U. Immunosuppressive acidic protein (IAP) and CA 125 assays in detection of human ovarian cancer: preliminary results. Int J Biol Markers 1987;2:187-90.
33. Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992;44:155-60.
34. Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, et al. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993;48:148-54. (Pubitemid 23075165)
35. Sawada M, Okudaira Y, Matsui Y, Shimizu Y. Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 1983;52:2081-5. (Pubitemid 14232251)
36. Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. Int J Cancer Suppl 1988;3:61-7. (Pubitemid 19044865)
37. Onsrud M. Tumour markers in gynaecologic oncology. Scand J Clin Lab Invest Suppl 1991;206:60-70.
38. Roman LD, Muderspach LI, Burnett AF, Morrow CP. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998;43:403-7. (Pubitemid 28244003)
39. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66.
40. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77. (Pubitemid 41502830)
41. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8. (Pubitemid 351174295)
42. Urban N. Specific keynote: ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol 2003;88:S75-9;discussion S80-3.
43. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-23. (Pubitemid 28405297)
44. Konno R, Takano T, Sato S, Yajima A. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000;6:3576-80.
45. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15. (Pubitemid 39286271)
46. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11. (Pubitemid 36993248)
47. Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T, Kurita N, et al. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol 2005;23:1463-72.
48. Xu FJ, Yu YH, Li BY, Moradi M, Elg S, Lane C, et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res 1991;51:4012-9.
49. Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol 1993;11:1506-10. (Pubitemid 23228255)
50. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90. (Pubitemid 39095590)
51. Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard MA, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007;2:369-75.
52. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009;200:639.e1-5.
53. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
54. Chen H, Hardy TM, Tollefsbol TO. Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011;2:67.
55. Soto-Reyes E, González-Barrios R, Cisneros-Soberanis F, Herrera-Goepfert R, Pérez V, Cantú D, et al. Disruption of CTCF at the miR-125b1 locus in gynecological cancers. BMC Cancer 2012;12:40.
56. Kosaka N, Ochiya T. Unraveling the mystery of cancer by secretory microRNA: horizontal microRNA transfer between living cells. Front Genet 2011;2:97.
57. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 2012;7:e30679.
58. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 2012;3:56.
59. Lässer C. Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Expert Opin Biol Ther 2012;12 Suppl 1:S189-97.
60. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta 2012;1826:103-11.
61. Krutovskikh VA, Herceg Z. Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. BioEssays 2010;32:894-904.
62. Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer - a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med 2012;50:601-15.
63. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9. (Pubitemid 41377683)
64. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. (Pubitemid 40343076)
65. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217-22. (Pubitemid 351508308)
66. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58. (Pubitemid 47187346)
67. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707. (Pubitemid 47437445)
68. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
69. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008;105:7004-9. (Pubitemid 351754520)
70. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21. (Pubitemid 351853251)
71. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
72. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS ONE 2012;7:e34546.
73. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes 2012;5:164.
74. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS ONE 2012;7:e30269.
75. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012 Feb 9. [Epub ahead of print].
76. Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Report 2012;5:1277-80.
77. Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol Chem 2012;393:319-30.
78. Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, et al. Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovarian Res 2012;5:2.
79. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 2012;279:2047-59.
80. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS ONE 2012;7:e33214.
81. Li J, Liang S, Jin H, Xu C, Ma D, Lu X. Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol Rep 2012;27:1835-42.
82. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012;27:1238-44.
83. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011;2:1265-78.
84. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012;586:1279-86.
85. Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, et al. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues]. Zhonghua Zhong Liu Za Zhi 2011;33:885-90. [Article in Chinese].